{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=DNA+Vaccine+placebo", "query": { "intervention": "DNA Vaccine placebo" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 68, "total_pages": 7, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=DNA+Vaccine+placebo&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-24T21:46:51.537Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04469179", "title": "Safety, Tolerability, and Pharmacokinetics of SAB-185 in Ambulatory Participants With COVID-19", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "COVID-19", "SARS-CoV2" ], "interventions": [ { "name": "SAB-185", "type": "BIOLOGICAL" }, { "name": "Normal Saline", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "SAb Biotherapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 21, "start_date": "2020-08-20", "completion_date": "2021-11", "has_results": false, "last_update_posted_date": "2021-10-26", "last_synced_at": "2026-09-24T21:46:51.537Z", "location_count": 3, "location_summary": "Miami Beach, Florida • Omaha, Nebraska • Sioux Falls, South Dakota", "locations": [ { "city": "Miami Beach", "state": "Florida" }, { "city": "Omaha", "state": "Nebraska" }, { "city": "Sioux Falls", "state": "South Dakota" } ], "official_url": "https://clinicaltrials.gov/study/NCT04469179" }, { "nct_id": "NCT01190176", "title": "Gynaecological Follow-up of a Subset of HPV-015 (NCT00294047) Study Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Infections, Papillomavirus" ], "interventions": [ { "name": "Gynaecological follow-up", "type": "PROCEDURE" }, { "name": "Cervarix", "type": "BIOLOGICAL" }, { "name": "Placebo control", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "28 Years", "maximum_age": null, "sex": "FEMALE", "summary": "28 Years and older · Female only" }, "enrollment_count": 34, "start_date": "2011-09-12", "completion_date": "2017-09-20", "has_results": true, "last_update_posted_date": "2019-10-30", "last_synced_at": "2026-09-24T21:46:51.537Z", "location_count": 3, "location_summary": "Iowa City, Iowa • Wichita, Kansas • Wenatchee, Washington", "locations": [ { "city": "Iowa City", "state": "Iowa" }, { "city": "Wichita", "state": "Kansas" }, { "city": "Wenatchee", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT01190176" }, { "nct_id": "NCT00801697", "title": "Safety and Immune Response to Preventive HIV Immunization With Adenovirus Serotype 5 or 35 Vector", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "DNA Vaccine", "type": "BIOLOGICAL" }, { "name": "DNA Vaccine placebo", "type": "BIOLOGICAL" }, { "name": "rAd35", "type": "BIOLOGICAL" }, { "name": "rAd35 placebo", "type": "BIOLOGICAL" }, { "name": "rAd5", "type": "BIOLOGICAL" }, { "name": "rAd5 placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 192, "start_date": "2009-02", "completion_date": "2015-04", "has_results": false, "last_update_posted_date": "2021-10-14", "last_synced_at": "2026-09-24T21:46:51.537Z", "location_count": 10, "location_summary": "Birmingham, Alabama • San Francisco, California • Decatur, Georgia + 5 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "San Francisco", "state": "California" }, { "city": "Decatur", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00801697" }, { "nct_id": "NCT07675629", "title": "Evaluating the Safety and Immunogenicity of Polyvalent DNA and Recombinant gp120 Protein HIV Vaccine (PDPHV) in Healthy, HIV-uninfected Adults", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Prevention" ], "interventions": [ { "name": "PDPHV Plasmid DNA Vaccines (env (A, B, C, A/E)/gag (C))", "type": "BIOLOGICAL" }, { "name": "PDPHV Recombinant Protein Vaccines (gp120 (A, B, C, A/E))", "type": "BIOLOGICAL" }, { "name": "Alhydrogel adjuvant", "type": "BIOLOGICAL" }, { "name": "GLA-SE adjuvant", "type": "BIOLOGICAL" }, { "name": "Placebo for DNA Vaccines, Protein Vaccines and Adjuvants", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Worcester HIV Vaccine", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 126, "start_date": "2026-09-01", "completion_date": "2029-08", "has_results": false, "last_update_posted_date": "2026-06-30", "last_synced_at": "2026-09-24T21:46:51.537Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT07675629" }, { "nct_id": "NCT04468958", "title": "Safety, Tolerability, and Pharmacokinetics of SAB-185 in Healthy Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "COVID-19", "SARS-CoV2" ], "interventions": [ { "name": "SAB-185", "type": "BIOLOGICAL" }, { "name": "Normal saline", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "SAb Biotherapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 28, "start_date": "2020-07-01", "completion_date": "2020-12-23", "has_results": false, "last_update_posted_date": "2022-07-01", "last_synced_at": "2026-09-24T21:46:51.537Z", "location_count": 3, "location_summary": "Wichita, Kansas • Syracuse, New York • San Antonio, Texas", "locations": [ { "city": "Wichita", "state": "Kansas" }, { "city": "Syracuse", "state": "New York" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04468958" }, { "nct_id": "NCT02431767", "title": "Evaluating the Safety and Immunogenicity of PENNVAX®-GP DNA Vaccine and IL-12 Plasmid, Delivered Via Intradermal or Intramuscular Electroporation in Healthy, HIV-Uninfected Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "PENNVAX®-GP HIV-1 DNA vaccine", "type": "BIOLOGICAL" }, { "name": "Interleukin-12 (IL-12) DNA adjuvant", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 94, "start_date": "2015-08", "completion_date": "2017-12-20", "has_results": false, "last_update_posted_date": "2021-10-15", "last_synced_at": "2026-09-24T21:46:51.537Z", "location_count": 4, "location_summary": "Decatur, Georgia • Rochester, New York • Nashville, Tennessee + 1 more", "locations": [ { "city": "Decatur", "state": "Georgia" }, { "city": "Rochester", "state": "New York" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT02431767" }, { "nct_id": "NCT06375512", "title": "A Study to Describe the Safety, Reactogenicity, and Immunogenicity of Herpes Zoster IN001 mRNA Vaccine (IN001) in Healthy Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Herpes Zoster" ], "interventions": [ { "name": "HZ Vaccine (IN001)", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" }, { "name": "Shingrix", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Shenzhen Shenxin Biotechnology Co., Ltd", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "50 Years", "maximum_age": "69 Years", "sex": "ALL", "summary": "50 Years to 69 Years" }, "enrollment_count": 150, "start_date": "2024-07-05", "completion_date": "2026-02-20", "has_results": false, "last_update_posted_date": "2026-03-31", "last_synced_at": "2026-09-24T21:46:51.537Z", "location_count": 1, "location_summary": "Hollywood, Florida", "locations": [ { "city": "Hollywood", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06375512" }, { "nct_id": "NCT00428337", "title": "Safety of and Immune Response to a DNA Vaccine and a Recombinant HIV-1-MVA Vaccine, Separately and in Combination, in Healthy Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "EP-1233", "type": "BIOLOGICAL" }, { "name": "MVA-mBN32", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "40 Years", "sex": "ALL", "summary": "18 Years to 40 Years" }, "enrollment_count": 36, "start_date": "2007-04", "completion_date": "2008-08", "has_results": false, "last_update_posted_date": "2021-10-14", "last_synced_at": "2026-09-24T21:46:51.537Z", "location_count": 3, "location_summary": "San Francisco, California • Rochester, New York • Nashville, Tennessee", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Rochester", "state": "New York" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00428337" }, { "nct_id": "NCT02851277", "title": "A Study to Evaluate Safety, Tolerability and Immune Response in Adults Allergic to Peanut After Receiving Intradermal or Intramuscular Administration of ASP0892 (ARA-LAMP-vax), a Single Multivalent Peanut (Ara h1, h2, h3) Lysosomal Associated Membrane Protein DNA Plasmid Vaccine", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Peanut Allergy" ], "interventions": [ { "name": "ASP0892 Intradermal", "type": "DRUG" }, { "name": "ASP0892 Intramuscular", "type": "DRUG" }, { "name": "Placebo Intradermal", "type": "DRUG" }, { "name": "Placebo Intramuscular", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Astellas Pharma Global Development, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 31, "start_date": "2016-12-13", "completion_date": "2018-12-06", "has_results": false, "last_update_posted_date": "2024-10-23", "last_synced_at": "2026-09-24T21:46:51.537Z", "location_count": 8, "location_summary": "Little Rock, Arkansas • Mountain View, California • Baltimore, Maryland + 5 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Mountain View", "state": "California" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02851277" }, { "nct_id": "NCT00249106", "title": "Safety and Immunogenicity of a Plasmid HIV Vaccine in HIV Uninfected Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infection" ], "interventions": [ { "name": "ADVAX", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "International AIDS Vaccine Initiative", "sponsor_class": "NETWORK", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 45, "start_date": "2003-12", "completion_date": "2005-10", "has_results": false, "last_update_posted_date": "2013-02-11", "last_synced_at": "2026-09-24T21:46:51.537Z", "location_count": 2, "location_summary": "New York, New York • Rochester, New York", "locations": [ { "city": "New York", "state": "New York" }, { "city": "Rochester", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00249106" } ] }